Lewy body Dementia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Lewy body Dementia – Pipeline Review, H2 2016’, provides an overview of the Lewy body Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia

The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects

The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Lewy body Dementia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Axovant Sciences Ltd.

BioArctic AB

Eisai Co., Ltd.

Immungenetics AG

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lewy body Dementia Overview 6

Therapeutics Development 7

Pipeline Products for Lewy body Dementia - Overview 7

Lewy body Dementia - Therapeutics under Development by Companies 8

Lewy body Dementia - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Lewy body Dementia - Products under Development by Companies 12

Lewy body Dementia - Companies Involved in Therapeutics Development 13

Axovant Sciences Ltd. 13

BioArctic AB 14

Eisai Co., Ltd. 15

Immungenetics AG 16

Sumitomo Dainippon Pharma Co., Ltd. 17

Takeda Pharmaceutical Company Limited 18

Lewy body Dementia - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Combination Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 26

Drug Profiles 28

(donepezil hydrochloride + glycopyrrolate) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(glycopyrrolate + rivastigmine) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BAN-0805 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

E-2027 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

intepirdine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

nelotanserin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

TAK-071 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

TAK-915 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

zonisamide - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Lewy body Dementia - Dormant Projects 42

Lewy body Dementia - Product Development Milestones 43

Featured News & Press Releases 43

Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia 43

Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia 44

Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Lewy body Dementia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Lewy body Dementia – Pipeline by Axovant Sciences Ltd., H2 2016 13

Lewy body Dementia – Pipeline by BioArctic AB, H2 2016 14

Lewy body Dementia – Pipeline by Eisai Co., Ltd., H2 2016 15

Lewy body Dementia – Pipeline by Immungenetics AG, H2 2016 16

Lewy body Dementia – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 17

Lewy body Dementia – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Assessment by Combination Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Lewy body Dementia – Dormant Projects, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for Lewy body Dementia, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports